Pharmaterials are delighted to announce that they have been granted a Queen's Award for Enterprise 2008 - the most prestigious business award in the UK.
PRESS RELEASE:
Pharmaterials receives Queens Award for Enterprise
Pharmaterials, a contract drug development company which provides preformulation and formulation services, has been awarded the Queens Award for Enterprise for International Trade. Parmaterials won the Award for increasing its International Trade by over 270 percent in three years, and now partners with over 80 companies in 16 countries worldwide. Its clients range from major multi national pharmaceutical companies to biotech start-ups.
Pharmaterials capabilities include state of the art polymorphism screening and advanced physical testing. It also has a well established formulation group providing solutions for the delivery of poorly soluble drug substances, such as through oral and intravenous delivery, and for inhalation.
Professor Graham Buckton, Chief Executive Officer and founder of Pharmaterials and Professor of Pharmaceutics at the London School of Pharmacy, said: “Pharmaterials strong science base, coupled with the excellent work of the staff has been enormously important in winning this Award. Pharmaterials philosophy is that we do not just make measurements, we provide a true understanding of our client’s challenges, and that is why we have seen such success.”
Mark Hooper, Pharmaterials Director of Business Development added: “In a competitive business market the success seen by Pharmaterials is due to the quality of the work that the staff provide. Communication with customers is key and we pride ourselves in doing this well.”
PII , the US based formulation and contract manufacturing organisation, acquired a controlling stake in Pharmaterials in January 2008, giving the ability to take a new chemical from early phase physico-chemical testing through to formulation, clinical trials supply and even commercial manufacture, providing the basis for further strong growth for Pharmaterials in the coming years.
Pharmaterials had its first year of trading in 2001, being formed as a spin out of the School of Pharmacy, University of London. The Company was formed on the platform of pharmaceutical materials science for which the London School of Pharmacy has an outstanding international reputation.
-ends-
About Pharmaterials: Pharmaterials Ltd is an early phase development company with extensive expertise in salt selection, polymorphism screening, pharmaceutical preformulation, amorphous materials, materials characterisation and formulations to facilitate the pharmaceutical development of low solubility drugs by oral and IV routes and inhaled drug delivery |
